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Rational Design of Peptides Binding towards Human PD-L1 Using Knob-Socket Model

Abstract

by Xingchen Zha
University of the Pacific
2018

Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein that has
been reported to play a vital role in mediating suppressed immunity. The interaction
between PD-L1 and PD-1 delivers a negative signal that reduces the proliferation of
these T cells and induces apoptosis at the same time. Antibodies that can block the
Programmed death-ligand 1 (PD-L1) on tumor cells have been shown to alleviate
cancer-induced immunosuppression. While antibodies have a great potential in various
therapeutic uses, many drawbacks such as the high cost of production, huge molecular
size, and poor permeability impose restrictions on the extensive use of full-length
antibodies. These limitations have necessitated research for finding alternatives to
antibodies, such as peptides, that have lower molecular weight and similar properties as
antibodies but do not have the lengthy and complicated approach of producing
antibodies.
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In this study, a novel approach based on molecular interactions of the PD1-PDL1 complex was developed to design peptides against PD-L1 using Knob-Socket model
as basis. Three generations of peptides, α-helix, over-packed and salt bridge function
peptides, were designed. All designed peptides were docked in the Molecular Operating
Environment (MOE) and the AutoDock Vina software for the docking energy and the
detail interaction information. Synthesis and characterization of selected peptides were
performed after simulation studies. Surface Plasmon Resonance (SPR) studies showed
that α-helix and over-packed peptides can’t bind to the PD-L1 protein with no response
on sensorgrams, while peptides with salt bridge function had a higher binding response
than those two generations of peptides. In confocal microscopic studies, PD-L1 positive
breast cancer cell line MDA-MB-231 was used to determine the binding specificity of
the salt bridge function peptides to PD-L1 in vitro, while another breast cancer cell line
(MCF-7, without PD-L1) was used as a control. After incubation with peptides,
significant fluorescence intensities were detected on the MDA-MB-231 cells, while only
background fluorescence was observed on MCF-7 cells.
In conclusion, this study demonstrated that peptides against PD-L1 designed
using the Knob-Socket model and molecular interaction between PD-L1-PD1 complex
showed feasibility to bind specifically with PD-L1 receptors.
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Chapter 1: Introduction

Cancer is a category of diseases caused by uncontrolled cell division and growth
with the ability to invade and destroy other parts of the body [1,2]. There are many
treatment options for cancer such as chemotherapy, radiation therapy, targeted therapy,
and immunotherapy. Chemotherapy is the predominant treatment for cancer and usually
comes with one or more cytotoxic anti-cancer drugs [3]. Ideally, these traditional
antineoplastic drugs such as 5-fluorouracil and cyclophosphamide can kill rapidly
dividing cancer cells but not the normal cells. However, the lack of tumor selectivity and
low potency impose restrictions on those drugs in chemotherapy. To overcome the
potency problem, more effort was put into the discovery of natural sources for efficient
drugs such as auristatins. However, the selectivity of these drugs, which could lead to
serious toxicity during the treatment, was still the significant problem for chemotherapy
[4].
Targeted therapy is a more specific therapy compared to the conventional
chemotherapy which has effects on both the fast-dividing cancer cells and normal cells.
Currently, targeted therapies are widely performed for breast cancer, melanoma,
lymphoma, and other types of cancer [2]. There are two types of targeted therapies,
active targeted therapy and passive targeted therapy. Passive targeting therapy was
employed in an approach to deliver drugs through capillaries which resulted in less
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accumulation on normal cells but selective accumulation on cancer cells. The
improvement selectivity was attributed to the increased permeation and retention
function [5,6]. Correspondingly, the treatment of drugs used for their interaction
specifically with molecular targets associated with cancers is called active targeted
therapy. The specific interaction can be used in both the cancer growth and spreading
stage.
1.1 Cancer immunotherapy
Cancer immunotherapy uses the immune system itself to treat cancer [7]. In the
past few decades, immunotherapy has become a significant way of treating different
types of cancer. Similar to targeted therapy, immunotherapies consist of active, passive,
and hybrid therapy. The cancer cell surface has molecules called tumor-associated
antigens, which can be determined by the immune system. Both active and passive
immunotherapies can take advantage of those molecules in guiding the targeted
response.
Antibody therapy is one of the most important immunotherapies [8]. The
immune system produces specific antibodies after detecting antigens on the cell surface.
Antibodies can utilize the cell surface receptors as targets for the treatment of a wide
range of cancers. An appropriate antibody could not only prevent the interference from
tumor cells but could also induce antibody-dependent cytotoxicity when it binds to a
targeting cancer antigen. All these functions could induce cell apoptosis and limit the
cancer development. There are many approved antibodies for immunotherapy on the
market such as Rituximab, Alemtuzumab, Nivolumab, and Ipilimumab. Therefore, the
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rational designing of a novel antibody for immunotherapy has a significant impact on
cancer study.
1.2 Antibody
Many immunotherapeutic regimens involve antibodies. Antibodies are a key
component of the adaptive immune response and play a central role in both recognizing
foreign antigens and stimulating an immune response. Antibodies are Y-shaped proteins
mostly produced by plasma cells and are composed of two regions: an antigen-binding
fragment (Fab), which binds to antigens, and a Fragment crystallizable (Fc) region,
which interacts with Fc receptors that are expressed on the surface of different immune
cell types including macrophages, neutrophils, and natural killer (NK) cells.
1.2.1 Structure of an antibody. As can be seen in Figure1.1, antibodies consist
of three parts that are combined by disulfide bonds. The two arms of the antibodies
account for the variable region (V) that is responsible for the binding of the antigen. In
the variable region, there are regions called complementarity-determining regions
(CDRs) that determine the binding specificity of antibodies. The constant (C) region
with less variability is the last part of the antibodies and can bind to other immune
molecules in the immune system. Many physiological functions such as lysis of cells
and recognition of immune particles need the involvement of the C region of an
antibody [9-11].
Antibodies consist of heavy chains and light chains. Heavy chains have the
following five isotypes: Immunoglobulin A (IgA), Immunoglobulin D (IgD),
Immunoglobulin E (IgE), Immunoglobulin G (IgG), and Immunoglobulin M (IgM).
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Immunoglobulin A (IgA) is an antibody that is distributed in mucous membranes
and plays a critical role in the immune system. Mucosal membranes produce more of
IgA than all the other types of antibodies [12]. More than three grams of IgA are
generated in the intestinal lumen, which takes up to 15% of all immunoglobulins
[13,14]. Immunoglobulin D (IgD), with molecular weight 185kDa, is an antibody that is
found in the plasma membranes of B-lymphocytes and the blood serum. The half-life of
IgD is 2.8 days [15]. Additionally, IgD can activate the antimicrobial function which
results in an increased immune surveillance [16]. Immunoglobulin E (IgE) is a type of
antibody that is secreted by plasma cells. IgE plays a vital role in protecting the immune
system from parasites such as helminths [17] (for example, Fasciola hepatica) and
Schistosoma mansoni [18-20]. It can also bind to the receptors on platelets and
eosinophils resulting in the activation of the immune system [21]. Immunoglobulin M
(IgM) is the largest antibody produced by vertebrates. It is the first antibody involved in
the response to an antigen [22,23]. Immunoglobulin G (IgG) is also generated by plasma
B-lymphocytes. IgG is a type of antibody with a molecular weight around 150kDa,
making up approximately 75% of the serum antibodies in humans [24]. IgG is also the
most common type of antibody in the human immune system [25]. IgG molecules with
two antigen binding sites are synthesized and released by plasma B cells. IgG can
protect the body from an infection by recognizing and binding pathogens such as viruses
and bacteria. Antibody-dependent cell-mediated cytotoxicity (ADCC) will be performed
after IgG binds to pathogens and makes them easy to be attacked [26].
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Figure 1.1 Structure of an Antibody
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1.2.2 Binding between antibody and antigen. The antigen-antibody interaction
mechanisms have been studied by various models for a long time [16, 27]. The body can
be protected from harmful foreign molecules, such as pathogens, by the antigenantibody interaction. Antibodies can bind to antigens with high specificity and affinity in
the blood, and then, the antigen-antibody complex is transported for deactivation.
In 1952, Richard J. Goldberg from the University of Wisconsin developed the
first correct definition of the antigen-antibody interaction [28,29]. It is also called the
"Goldberg's theory" [30].
The flexibility of antibodies has been studied by scientists for a long time. Many
different techniques such as fluorescence depolarization and X-ray crystallography have
been used to determine the flexibility of the antibodies’ conformation [24]. To bind with
an antigen, the constant domain of an antibody can change dramatically in the X-ray
crystallography studies [26,31,32].
Each antibody can bind to one or multiple specific antigens based on the
conformational flexibility. Manivel V et al. proved this mechanism based on the
thermodynamic analysis [33]. Additionally, James et al. also determined the
conformational flexibility of an antibody based on their research through
crystallographic studies and the results showed that an antibody can bind to different
antigens [34].
For the antibody-antigen interaction, tyrosine and tryptophan are abundant on the
binding interfaces while less charged residues such as glutamate, lysine except for
arginine. Tyrosine, with a large hydrophobic surface, could form hydrogen bonds with
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antigen for its hydroxyl group. Arginine can build hydrogen bonds and salt bridges
based on its guanidinium part and three hydrophobic methylene carbons [35,36].
However, not all the six CDRs have a connection with the antigen on the
antigen-antibody interface. It is known that a minimum of four CDRs can bind to
antigens [37]. Camelid single-domain antibodies, however, can bind to antigens though
it has only two CDRs in its nanomolar ranges [38]. VH CDRs have more extensive
interaction with antigen than VL CDRs [39]. Besides, some antigens such as peptides
with a grooved contacting surface can bind to special sockets on the antibodies, which
are different from the large protein antigens with planar surface [40].
The binding of an antibody to its antigen is determined by affinity and
specificity. The binding can be reversed and determined by the reactants concentrations.
The antibody-antigen complex has a balance rate between formation and dissociation at
the equilibrium phase. An affinity constant (KD) can be calculated based on the associate
and dissociate rate constants. The high affinity of the antibody-antigen complex usually
comes with the small KD. Normally, KD values of antibodies are in the range of 10-6 to
10-9. Antibodies with KD values in the low nanomolar range (10-9) can be considered as a
high affinity. Additionally, the specificity of the binding is attributed to the specific
chemical structure of each antibody. Some small residues in the CDR1 and CDR2 of VH
determine the binding specificities of the individual antibodies. The principles of
specificity of the antigen-antibody interaction are valuable in the clinical laboratory for
diagnostic purposes. The most basic application is in the determination of the ABO
blood group, useful for blood transfusion [41]. It is also performed as a molecular
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technique for infection with different pathogens, such as helminth parasites, HIV, and
microbes.
1.2.3 Development and categories of an antibody. In 1890, Emil von Behring
and Shibasaburo Kitasato built a theory for antibodies. They found that infected animals
suffering from diphtheria can be cured by the transfer of therapeutic serum from
immunized animals [42,43]. Behring won the Nobel Prize in 1901 for the work in
potential treatment in humans [44]. In 1900, the side-chain theory was developed by
Paul Ehrlich, in which he proposed the hypothesis that side-chain receptors on cells can
interact with a given pathogen. In his model, he assumed that an antibody can bind to
foreign molecules called antigens and activate the complement pathway. The ‘lock and
key’ theory developed by Emil Fischer came to the same conclusion as this model
[45,46]. In 1948, Astrid Fagraeus proposed that an antibody was secreted by plasma B
cells, and later in 1957, the clonal selection theory was given by Frank Burnet and David
Talmage [47]. This theory was different from the model developed by Linus Pauling in
1940 and stated that the antigen acted as a template for the antibody [48].
Gerald Edelman and Rodney Porter won the Nobel Prize jointly in 1972 for their
independently publishing of the molecular structure of antibodies in 1959 [49-51]. The
first antibody fragment atomic resolution structure was published in 1973 [52].
Furthermore, the modern research of antibodies began based on the discovery of
monoclonal antibodies by Georges Köhler and César Milste in 1975 [53].
An antibody can be produced from many different systems such as yeast bacteria
and mammalian cell systems. Humans with non-glycosylated proteins can obtain it from

24

bacteria such as Streptomyces and Escherichia coli. Only simple media was needed for
protein growth with a range between 1 to 300 mg/L from the bacteria system [54]. But it
is impossible to perform further modifications and collect full-size antibodies from the
bacteria system. Additionally, expression levels of protein will reduce due to the loss of
plasmid during bacterial culture.
Yeast is another production, but inefficient, system for antibodies. Each liter of
yeast medium could only generate few microgram antibodies until the 1980s [55]. Then,
the methylotrophic yeast was developed, which produced antibodies with an increased
productivity of 100 milligrams per liter yeast [56].
More complicated proteins such as full-size antibodies can only be obtained from
the mammalian cells system. However, the high cost of the cell culture media and
instruments impose restrictions on the development of mammalian cells system [57,58].
Therefore, it is better to obtain economically complex recombinant proteins from
transgenic plants and animals instead of the traditional mammalian cells system.
During the past several decades, great progress has been made in the field of
antibody discovery and therapy with a total of over 300 unique monoclonal antibodies
investigated in clinical trials.
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Figure 1.2 History of antibody research [42].
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Figure 1.3 Evolution of therapeutic antibody technology.
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1.2.4 Polyclonal and monoclonal antibodies
1.2.4.1 Polyclonal antibodies. Polyclonal antibodies (pAbs) are generated by
different B cell lineages within the body while monoclonal antibodies (mAb) are only
secreted by a single cell lineage. Polyclonal antibodies are a mixture of immunoglobulin
molecules that bind to a specific antigen, each identifying a different epitope.
Polyclonal antibodies with different specificities and affinities are stable in a pH
and salt concentration range [59]. Compared to other mammals producing polyclonal
antibodies, the rabbit is the most significant production source of polyclonal antibodies
for its low cost of maintenance and simple handling. Polyclonal antibodies are generally
obtained by immunizing animals through intradermal and subcutaneous injections. The
immune response was increased by using antigens with adjuvants such as bovine serum
albumin [60].
1.2.4.2 Monoclonal antibodies. Monoclonal antibodies (mAb) are made by
identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies
are homogenous and can bind to the same epitope. These monoclonal antibodies have
similar immunochemical function due to the derivation of a single B cell clone of one
animal while polyclonal antibodies bind to multiple epitopes and are generated by
several different plasma cell lineages. Most monoclonal antibodies are obtained from
rabbits and mice. By changing the therapeutic targets of one single monoclonal antibody
to two epitopes, bispecific monoclonal antibodies can also be modified and obtained.
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Figure 1.4 Monoclonal antibody production.
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1.2.5 Limitations of current antibody. As the pharmaceutical market in the
world continues to expand, biopharmaceutical products such as therapeutic mAbs play a
more significant role in cancer treatment. Approximately 60% of biopharmaceutical
sales is attributed to monoclonal antibody products, and these products have grown to
almost $90 billion in the past three years. A worldwide sales of monoclonal antibody
products will take place in the future. However, getting treated with mAbs still has side
effects such as tumor lysis syndrome and anaphylaxis [61].
Poor tumor permeability is another limitation of antibodies regardless of the
adverse effects of mAbs. In the tumor microenvironment, the number of functional
lymphatic vessels are not sufficient enough to transport the macromolecules such as
mAbs [62]. The potential of an antibody treatment is reduced since it is difficult for
mAbs to penetrate deeply into the tumor microenvironment.
Additionally, the mAbs treatment currently available on the market is very
expensive. The average annual cost of an mAb treatment was $96,731, and the
Herceptin costs for the treatment was $43080 per year [63]. The production cost and
development time also determine the application of antibodies. It took about 10 years for
a mAbs to come to the market including the discovery and research time. In addition to
this, the cost of mAbs development is over $650 million, which is very high.
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1.2.6 Antibody alternatives. Since mAbs have many disadvantages as
mentioned above, alternatives to antibodies have been created for the market. These
molecules, with lower molecular weight, usually have a similar function such as binding
specificity, affinity, and tissue penetration. These alternatives include Fab, nanobodies,
single chain fragment variable (scFv), antibody mimics [64,65], and so on. Furthermore,
the research and screening time of antibody alternatives is shorter than a monoclonal
antibody. Compared with the traditional mAbs, these molecules with lower molecular
weight can easily penetrate to the tumor site and bind to an antigen.
1.2.6.1 Single chain fragment variable (scFv). Single chain fragment variable is
a protein consisting of the variable regions of the heavy and light chains of
immunoglobulins [66]. scFv can be employed to build molecules for different purposes
due to the retainment of the binding specificity and affinity of a full antibody [67-69].
However, scFv with a molecular weight around 25kDa has a limitation of lower halflife, making it difficult to be used in the market [70]. Two scFvs can be connected by a
peptide linker or a disulfide bond [69,71-73]. E. coli bacterial with an ability to generate
foreign protein in a large amount can secrete scFv at a high speed [74]. Generally,
mRNA is isolated from the hybridoma [75-77] or spleen cells from immunized mice
[78,79] or B lymphocytes [80,81] and is reverse transcribed into DNA followed by gene
amplification by the PCR technique. The only issue with this approach is that some
protein lacks certain conformation due to the limited folding capacity of the E. coli
bacterial system. The problem has been studied by many reports [82,83].
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1.2.6.2 Antibody mimic. Antibody mimic is a molecule that can bind to a protein
with specificity and affinity. The molecular weight of an antibody mimic is less than 10
kDa [84]. Antibody mimic can bind to an antigen with no risk of ADCC and CDC
because of the lack of constant region of an antibody. There are many different
approaches such as phage display, mRNA display, and yeast two-hybrid system for the
development of antibody mimics [85,86].
In 1998, the first antibody mimic was designed to bind to TNF-α by performing a
phage display [87]. However, the binding affinities of the isolated peptides were too low
for them to be used for treatment. A lot of effort has been put on the discovery and
screening for antibody mimics with KD values in the picomolar to the millimolar range
[88,89]. The three-amino-acid motif RGD, developed by a phage display technique, is
one of the most promising examples among them. This motif with a KD of 0.8 nM can
bind to the αVβ3 integrin that forms the tumor vascular endothelial cells [90].
Chemical synthesis is another feasible approach to obtain antibody mimics.
Before synthesis, a mass of molecular docking should be done between the screening
peptides with a random sequence and a library of thousands of human proteins [91]. Rod
Balhorn et al. discovered selective high-affinity antibody mimics that target leukemia or
lymphoma through molecular docking [92]. However, all docking based on these
screenings are tedious and time-consuming due to the trial-and-error principle.
Therefore, a rational design of peptides based on the molecular interaction between
antibody and antigen can be considered as a viable approach.
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1.3 Programmed Death-Ligand 1
Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein
that has been studied to play a critical role in mediating the suppressed immune function
during specific events such as tissue allografts and autoimmune diseases. This molecule
was named as PD-L1 due to its identification as a ligand of PD-1 after its first
characterization by Mayo Clinic as an immune regulatory molecule, B7-H1 [93]. The
immune system takes the response to foreign antigens that are relative to both exogenous
and endogenous danger signals, which causes an activation and proliferation of the
antigen-specific T cells. The interaction between PD-L1 and PD-1 delivers a negative
signal to these T cells and results in the reduced proliferation of T cells [94].
Blockade of PD-L1 can limit the growth of tumors in the presence of immune
cells while most cancer cells have the ability to express high levels of PD-L1. A
conclusion can be made that tumor cells can escape immune attack with PD-L1 [95].
PD-L1 can modulate activation or inhibition upon binding with its receptor PD-1, which
is located on activated T cells, B cells, and myeloid cells. Said et al. found that PD-L1
can induce IL-10 production when interacting with PD-1 which is upregulated on
activated CD4 T-cells [96].
It is reported that the upregulation of PD-L1 could help cancers to escape attack
from the host immune system. Antibodies that can block PD-L1 on tumor cells have
shown the ability to alleviate cancer-induced immunosuppression [97]. Many PD-L1
inhibitors such as durvalumab, atezolizumab, and avelumab are in development as
immuno-oncology therapies and are showing good results in clinical trials [98,99]. PD-
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L1 has been considered as a potential target for a receptor-mediated delivery system of
peptides, antibodies, or drugs for cancer treatment.
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Figure 1.5 Mechanism of PD-L1 delivers T Cell Suppression and Tumor Cell Survival [100].
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1.4 Statement of the Problem
Antibodies have been commonly used as reagents to recognize antigens or
proteins in life science research due to their binding specificity. Recently, several
antibodies have been successfully developed for therapeutic uses. However, extensive
uses of antibodies are limited by their high cost of production, long production period,
and poor stability. These limitations have necessitated research for finding antibody
alternatives with lower molecular weight and similar properties as antibodies but without
the limitations of the lengthy and complicated approach of producing antibodies. Some
examples of these efforts include fragment antigen binding (Fab) and scFv, or synthetic
antibody mimics. Though these molecules have lower molecular weight when compared
with antibodies, they still have the disadvantages of tedious and time-consuming
processes, the uncertainty of the outcome, and high costs of production. A rational
design of molecules that can mimic the antibody-antigen interaction based on the
molecular interaction and Knob-Socket model can be considered as a viable approach
for antibody alternatives. In this study, we proposed an approach to design peptides
against a target without involving massive experimental screening trials.
1.5 Hypothesis
Rationally designed peptides that specifically bind to PD-L1 based on molecular
interactions between the ligand-receptor and Knob-Socket model.
1.6 Specific Aims
The objective of this dissertation research is to design, synthesize, and
characterize novel peptides for binding PD-L1 based on the PD1-PD-L1 interaction and
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Knob-Socket model. To achieve the research objective, the specific aims are described
as following:
1. To design peptides based on the Knob-Socket model and protein-protein
interaction. Peptides which can specifically bind to the PD-L1 and scrambled
(control) sequence peptides are designed.
2. To perform computer simulation studies and to determine the number of
interactions, docking energy, and binding position by Molecular Operating
Environment (MOE) and AutoDock Vina software. Selected peptides based on
these parameters are utilized for future studies in vitro.
3. To synthesize and characterize peptides. Designed peptides and scrambled
sequence peptide with and without the FITC conjugation are synthesized using
the solid phase synthesis method. The purity and mass to charge ratio will be
determined by the high-performance liquid chromatography (HPLC) and mass
spectrometer.
4. To study the in vitro binding specificity and affinity of peptides to PD-L1. The
binding affinity and specificity will be determined by performing the Surface
Plasmon Resonance (SPR) technique and cell uptake experiments with confocal
microscopy.
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Chapter 2: Design and Computational Studies of Peptides
2.1 Introduction
In life sciences, antibodies are commonly performed to bind to different targets
with significant affinity and specificity in various areas such as therapeutic agents. When
compared with antibodies, peptides are much smaller in mass and size. Peptides can
simulate the interaction between antibodies and antigens with a small molecular weight.
Additionally, due to their small structure, they can penetrate tumor tissues easily and are
unlikely to trigger immunogenicity [101].
Molecular modeling is performed to predict the structure of biological molecules
and simulate the binding functions between the receptor and ligand in biological and
chemical systems. In this part, peptides are designed against the target based on the
molecular interactions between the antibody and antigen instead of complicated
experimental screening trials.
Molecular Operation Environment (MOE) is widely used as a drug discovery
software in different fields of molecular modeling, protein and antibody modeling, and
fragment and structure-based designing. The docking program in MOE can be
performed to mimic the interaction between two molecules based on their crystalline
structures. The possible orientation of two molecules can be obtained and analyzed in
the docking program. MOE can be used to screen the molecules based on the estimated
binding energy from the docking program. A stable system usually has a lower binding
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energy suggesting a possible interaction between two molecules. Also, a map with
detailed interaction on the interface between the two molecules can be determined by the
ligand interaction function in MOE. In other words, we can identify and select the
specific amino acid sequences in the binding interface that are significant for the
receptor to bind ligands.
AutoDock Vina is another screening software for molecular modeling which can
perform to determine the average accuracy of the binding mode predictions. It is an
important program for molecular docking and virtual screening. Vina performs a
sophisticated gradient optimization approach in its local optimization procedure. The
calculation of the gradient effectually offers the optimization algorithm a direction from
a single evaluation. By using multithreading, multiple CPUs or CPU cores can be
employed by Vina to speed up the calculation in screening molecules. After docking in
the AutoDock Vina, designed peptides can be screened based on the binding position
against the PD-L1 protein. Only peptides bound to the designed binding interface from
PD-L1 can be considered as important candidates.
PSIPRED is a precise and simple secondary structure prediction approach,
incorporating two feed-forward neural networks which carry out an analysis on output
got from PSI-BLAST (Position Specific Iterated - BLAST). The secondary structure of
peptides that we designed can be predicted by PSIPRED.
The interaction between PD1 and PD-L1 has been extensively studied by
scientists [102,103]. The three-dimensional structures of the different PD1-PD-L1
complex can be observed and identified based on the crystalline structure obtained from
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the Protein Data Bank (PDB). Core amino acids from the binding interface of the PD1PD-L1 complex can be collected and employed to design the peptides for PD-L1 after
analyzing the binding details.
The interaction between the novel peptide and PD-L1 was optimized by using
the Knob-Socket model developed by Joo et al. [104]. The packing between the
interactions of two molecules can be analyzed and explained by this model in a
simplified and straightforward approach. When it is compared with the other packing
models, the Knob-Socket model can be used to determine and optimize all kinds of
packing in the secondary structure [105]. In this model, Knob-Socket is defined as a
four-residue tetrahedral: one knob B in one secondary structure packed into a three
residue H: YX socket presented on the other secondary structure (Figure 2.1). The X
and Y are consecutive residues that pack with the covalent peptide bond (continuous
black line), where the hydrogen bond (broken red line) connects X and H. The H and Y
residues only connect by their side-chain interactions. Additionally, three types of
sockets were provided in the Knob-Socket model: a free socket with no packing knob,
filled socket with a packing knob, and a non-socket. The amino acid propensities
determine the packing strategy for choosing the binding peptide sequences in these three
types of socket.
A two-dimensioning map can be obtained with the information of sockets formed
on PD-L1 and specific binding knobs from PD1 in the principle of the Knob-Socket
model. Furthermore, a particular amino acid sequence that has a high frequency to be
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filled into sockets on PD-L1 can be determined and can be used for optimizing and
designing the peptides against PD-L1.
In this chapter, by using the Knob-Socket model, the interaction between
different PD1-PD-L1 complexes was analyzed and studied for the designing of the novel
peptide sequences towards PD-L1.
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(a)

(b)
(c)
Figure 2.1 Two-dimensional schematic of Knob-Socket model.

(a) A two-dimensional representation of the Knob-Socket model shows that the three residues
X, Y, and H in the socket are all packed against a knob residue B from the other secondary structure.
(b) The four-residue motif is arranged in the tetrahedral structure. All residues are represented by spheres.
The knob residue B connects to all the three socket residues only through side-chain interactions.
(c) The Knob-Socket model shown between two α-helices.
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Figure 2.2 Knob-Socket Propensity of various knobs to sockets. Adapted from Hyun Joo et al [114].
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2.2 Materials
UCSF-Chimera package (Version 1.10, San Francisco, CA, USA), MOE
software (Version 2013.08) from Chemical Computing Group Inc. (Montreal, QC,
Canada), AutoDock Vina from Scripps Research Institute (La Jolla, CA, USA).
PSIPRED from University College London (London, United Kingdom).
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2.3 Method
2.3.1 Design of peptides. Peptides were designed based on the crystal structure
of PD1-PD-L1 and the Knob-Socket model. The crystal structures (PDB 3SBW and
5IUS) were analyzed to determine which residues in PD-1 have maximum interaction
with the PD-L1 epitopes. For the first and second generations of peptides, the PD-L1
protein surface was identified to provide sockets in the two-dimensional map with
binding knobs from PD1 by analyzing the crystal structure PDB 3SBW.
Correspondingly, crystal structure PDB 5IUS was used for designing the third
generation of peptides. Each amino acid knob residues from the PD-1 is in contact with
the socket formed by the three amino acid residues on the PD-L1 surface. Based on the
probability of packing the amino acid knob to a different socket, peptides were designed
in an approach of linking the identified knob. Franking amino acids can be used to fill
the space when the distance between two residues is a lot. Different peptide sequences
can be designed by combining the amino acids from the list of possible knobs with
various sockets. For the α-helix peptides, 12 different peptide sequences were designed
in 25 amino acids length. To increase the stability and build an α-helix structure, several
amino acids were added to the start and end of the peptide sequences. The key amino
acid knobs from α-helix peptides were used to design the over-packed peptides with a 13
amino acids length. Correspondingly, the third generations of peptides, the peptides with
salt bridge function, have 67 peptides sequences including one scrambled sequence
peptide as a negative control.
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2.3.2 Secondary structure prediction for peptides in alpha helix design. The
secondary structure of peptides in alpha helix design was predicted by PSIPRED.
Several UCL structure prediction techniques were combined into one location by the
PSIPRED Protein Sequence Analysis Workbench. The results of the prediction were
received after submitting a protein sequence.
Peptides with high ratio of alpha helical structure and confidence of prediction
were then selected for further experiments and were docked in the AutoDock Vina to
check whether they could bind to the designed part of the target protein for further
screening.
2.3.3 Computer modeling studies. The crystalline structure of the PD-PD-L1
complex that was downloaded from the protein databank with PDB ID:3SBW and 5IUS
was analyzed in Chimera and optimized in MOE. Molecular Operating Environment
(MOE) was performed to determine the binding interface between the ligand and
receptor. The binding socket from PD-L1 and the amino acid knobs from PD1 were
assigned for the docking study by the atom selector. We can obtain the detailed
interaction map between PD-1 and PD-L1 by ligand interaction simulation. Furthermore,
core amino acid sequences for the design of peptides can also be analyzed and
determined by the direct interaction sequence from ligand interaction simulation.
Designed peptides were screened by utilizing the Molecular Operating
Environment (MOE) and the AutoDock Vina software. After performing energy
minimization, the conformation of the peptide with the lowest energy was docked in the
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MOE software to calculate the binding energy. The lower (negative) suggests better
binding.
Peptides with more number of interactions, preserved interactions, and lower
docking energy were then selected for further experiments and were docked in the
AutoDock Vina to check whether they could bind to the designed part of the target
protein for further screening.
2.4 Results and Discussions
2.4.1 Design of peptides. Peptides were designed based on the PD1-PD-L1
crystal structure and the Knob-Socket model. Taking the frequency data of knob and
sockets from Figure 2.2, the design of peptide sequences was determined by the
propensity of preferable knobs to sockets. The map and ribbon diagram of the PD-L1
surface bound by PD1 for α-helix and over-packed peptides are shown in Figure 2.3.
The knob positions from the ligand are represented as spheres. The pink color represents
knobs from PD1 in a covalent bond. Correspondingly, the map and ribbon diagram of
the peptides with the salt bridge function is shown in Figure 2.4. The side-chains of the
amino acids are also displayed, and the knob positions from the ligand are shown as
spheres. The orange color represents knobs from PD-1 in a covalent bond and red
represents the salt bridge function.
For the α-helix and over-packed peptide sequences, the packing interface lattice
diagram consisting of knobs and sockets is shown in Figure 2.3 (left). The filled sockets
are in grey and free sockets with no binding knobs are in yellow. The knobs are
presented in the same color as the ribbon diagram.
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Based on the mapping data, the key amino acid sequences are designed as shown
in Figure 2.5. The α-helix peptide sequences are designed based on these 13 amino
acids. To increase the stability and build an α-helix structure, several amino acids are
added to the start and end of the peptides. There are 25 α-helix amino acids in total.
Furthermore, over-packed peptides are designed by the 13 key amino acids as shown in
Figure 2.6.
Additionally, the sequences of third generation peptides are shown in Figure 2.7.
Arginine was chosen as the first amino acid for its basic side chain that can bind to the
acidic part of the protein shown on coulombic surface coloring; “a double anchor” with
glutamic acid and aspartic acid. The second amino acid, lysine, was also chosen because
it can bind to glutamic acid. The third, fifth, and seventh amino acids were selected
based on the propensity of the Knob-Socket model. Proline was used to give a turn off in
the fourth position. For the sixth position, serine was added to increase the hydrophily of
the peptide. Glycine was used in the eighth position as a franking amino acid. Glutamine
was used for its propensity in socket ADY. Threonine and glutamic acid were used for
its salt bridge. Histidine had a connection with aspartic acid. Knobs in pink and red that
have high preference such as Leu (L), Glu (E), Phe (F), and Tyr (Y) were filled in the
sockets and were connected based on the space between them and the other amino acids.
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Figure 2.3 Mouse PD-1 mutant and human PD-L1: Ribbon diagram of the PD1-PD-L1 interface (right) and
schematic of the interaction map diagram (left).
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Figure 2.4 High affinity mouse PD-1 and human PD-L1: Ribbon diagram of the PD1-PD-L1 interface (right)
and schematic of the interaction map diagram (left).
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Figure 2.5 Mouse PD-1 mutant and human PD-L1: α-Helix Peptides designed based on the PD1-PD-L1
interaction map diagram.
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Figure 2.6 Mouse PD-1 mutant and human PD-L1: Over-packed Peptides designed based
on the PD1-PD-L1 interaction map diagram.
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Figure 2.7 High affinity mouse PD-1 and human PD-L1: Peptides with SB function designed
based on the PD1-PD-L1 interaction map diagram.
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2.4.2 Secondary structure prediction for peptides in alpha helix design.
Peptides were selected based on the result of the ratio of alpha helical structure and
confidence of prediction. The sequences and prediction results of α-helix peptides are
shown in Figure 2.8. PDL1-01-25MER was chosen based on the high ratio of alpha
helical structure and confidence of prediction.
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Figure 2.8 Prediction results of peptides in α-helix design.
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2.4.3 Computer modeling studies. Peptides were selected based on the result of
the total number of interactions, preserved interactions, and docking energy. The
sequences and docking results of over-packed peptides are shown in Table 2.1. For overpacked peptides, PDL1-06-13MER was chosen based on the lower docking score. For
the peptides with salt bridge, PDL1-P13-01, PDL1-P13-28, PDL1-P13-40, and PDL1P13-55 were selected based on their lower binding energy as shown in Table 2.2.
A conclusive docking was performed by AutoDock Vina in terms of the total
number of interactions, preserved interactions, and docking energy, and the results are
shown in Table 2.3. The α-helix and over-packed peptides with a higher binding energy
and with a less number of total and preserved interactions suggested poor binding
affinity and specificity.
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Table 2.1 Docking results of over-packed peptides.
Ranking
Peptide No.
Sequence

Docking Score

1

PDL1-06-13MER

IAKARAQLEQFAS

-11.11

2

PDL1-07-13MER

EARAIAQLRELFA

-11.01

3

PDL1-09-13MER

EAAERAQYEQFLS -10.93

4

PDL1-12-13MER

LAKQIAEYRALLE

-10.68

5

PDL1-08-13MER

LAKARAELAQFIK

-10.66

6

PDL1-01-13MER

EARKIAELEQFLE

-10.54

7

PDL1-02-13MER

EARERAEIEALLS

-10.43

8

PDL1-10-13MER

EAKARAQYEQILA -10.36

9

PDL1-11-13MER

LARKIAELEKLLA

-9.98
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Table 2.2 Docking results of peptides with salt bridge function.
Top 20%: 13
Ranking
Sequence

4 Run

Results

1

PDL1-P13-28

-15.5482

2

PDL1-P13-14

-15.4521

3

PDL1-P13-53

-15.4139

4

PDL1-P13-31

-15.1848

5

PDL1-P13-1

-15.1122

6

PDL1-P13-32

-15.0183

7

PDL1-P13-45

-14.8636

8

PDL1-P13-11

-14.7244

9

PDL1-P13-62

-14.7051

10

PDL1-P13-55

-14.6899

11

PDL1-P13-8

-14.5711

12

PDL1-P13-60

-14.551

13

PDL1-P13-40

-14.5242

28

PDL1-P13-33

-14.0458

37

PDL1-P13-X (Control)

-13.8937
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Table 2.3 Peptides sequence with molecular modeling results.
Name
Sequence
Energy
Preserved
(kcal/mol) interactions
α-helix
PDL1-01
YGNLARKIAELEK-4.1
0
25MER
LLAEAQQREALG

Total
interactions
10

Over-packed

PDL1-0613MER

IAKARAQLEQFAS

-4.0

1

6

Peptides with
SB function

PDL1-P13-01

RKIPLSIGQTHSE

-5.6

2

11

PDL1-P13-28

RKFPLSKGQTHSE

-5.5

3

15

PDL1-P13-33

RKFPSSFGQTHSE

-4.7

2

10

PDL1-P13-40

RKIPHSKGQTHSE

-5.4

2

11

PDL1-P13-55

RKVPHSIGQTHSE

-6.1

6

12

PDL1-P13-X
(control)

RQSKLHPGSKTFE

-4.4

0

7
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AutoDock Vina was used to perform a second screening for the selected peptides
from the MOE software. From the Figure 2.9, we can determine that only PDL1-P13-55
can bind to the designed part of the target protein.
In this study, a screening approach of potential molecules to a given target was
evaluated by using the MOE and AutoDock Vina software. The optimized potential
energy was used in docking software instead of the free energy of the protein. Three
generations of peptides were designed based on the molecular interaction between PDL1 and PD-1 and were optimized by utilizing the Knob-Socket model. α-helix and overpacked peptides selected from MOE suggested that these molecules might not bind to
PD-L1. Besides, the third generations of peptides showed the binding preference against
the PD-L1 protein, based on the docking results from MOE and AutoDock Vina. The
binding between the designed peptides and PD-L1 still needed verification in
experiments. Based on the docking results from MOE and AutoDock Vina, PDL1-0125MER, PDL1-06-13MER, PDL1-P13-01, PDL1-P13-33, PDL1-P13-28, PDL1-P13-40,
and PDL1-P13-55 were selected for future studies.
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Figure 2.9 Binding position of PDL1-P13-55 in AutoDock Vina.

61

Chapter 3: Synthesis and Characterization of Peptides for PDL1
3.1 Introduction
The established method for synthesizing peptides in the lab is known as solidphase peptide synthesis (SPPS) [106]. This method was developed by Robert Bruce
Merrifield in 1963 [107,108] and it has frequently been used to synthesize different
peptides and proteins. SPPS leads to high yields of pure products and saves more time
than traditional synthesis such as liquid-phase peptide synthesis (LPPS). The advantages
of this method are very impressive. In the replacement of a complicated isolation
procedure, lots of time is saved for each intermediate product with a simple washing step
[109]. Additionally, this technique is feasible as well for automatic peptide synthesizers
that are commercially available. However, this method has the disadvantages of low
output since there are many cycles of coupling and deprotection for each amino acid in
the peptides synthesis and the intermediates cannot be purified after each coupling.
The key feature of SPPS is the continuous attachment of amino acids to a solid
support bead called resins. The chemical structure of the resin that we will use in the lab
is shown in Figure 3.1 (called Wang resin). The hydroxyl group is the place of
attachment to the C-terminal amino acid in the peptide chain. The rest of the peptide is
then synthesized by coupling one amino acid at a time [106]. Wang resin will keep
strong bondage to the peptides until cleaved by trifluoroacetic acid (TFA). These solid
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resins build a synthesis environment in which the peptide sequences being attached will
not cross a filter in the synthesis vessel.

Figure 3.1 Wang resin

Each amino acid has both an amine and carboxylic acid functional group, which
would result in side recreation through the synthesis process. Therefore, it is significant
to consider the protection strategies. 9-Fluorenylmethoxycarbonyl (Fmoc), used as the
protecting group, is commonly used in the peptides synthesis experiment. The Nterminal of each amino acid will be protected with Fmoc, and only the amino acid at the
end of C-terminal of the sequence will be attached on to the Wang resin [110,111].
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It is necessary to protect the side chain with protecting groups such as tertbutyloxycarbonyl (Boc) and tert-butyl (tBu) to prevent degradation during synthesis.
These protecting groups are stable enough in their basic conditions [107]. Additionally,
these protecting groups are convenient due to their instability in acid and will be cleaved
by the TFA in the final cleavage step.
The first amino acid usually has an attachment to Wang resin. Therefore, the first
step is removing the Fmoc group on the C-terminal amino acid by employing a base
such as mild basic solution 20% piperidine in DMF. The second Fmoc-protected amino
acid is then attached utilizing a coupling reagent such as diisopropylcarbodiimide (DIC)
and 1-hydroxybenzotriazole (HOBt) to make the reaction. Besides, several other
coupling agents such as 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU), and 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HATU) that require a base for activation were
employed with N, N-Diisopropylethylamine (DIPEA) in peptide synthesis. The
completion of each reaction is analyzed and confirmed by the Kaiser test based on the
different colors.
After the final coupling and deprotection of the peptide, trifluoroacetic acid
(TFA) can be used to cleave the peptide from the solid support. Peptides were separated
by using ice-cold diethyl ether from the cleavage cocktail solution. The peptides can be
characterized after lyophilization. Mass spectrophotometric techniques were used to
confirm the molecular weight of peptides and high-performance liquid chromatography
(HPLC) was used to detect and purify peptides.
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Circular dichroism (CD) is dichroism involving circularly polarized light, in
other words, the differential absorption of left- and right-handed light. CD spectroscopy
has a wide range of applications in many different fields, such as determination of the
secondary structure of proteins. The far-UV CD spectrum of proteins can reveal
important characteristics of their secondary structure. The typical CD spectrum of alphahelix, the beta-sheet, and random coil are shown in Figure 3.3. The alpha helix of
proteins has CD spectral signatures representative of their structures. The secondary
structure of peptides designed in α-helix method can be checked by CD.
A series of peptides to PD-L1 will be synthesized by using the solid phase
synthesis method. HPLC will be used for the purification of peptides and ESI-MS will
be used for determining the m/z value of peptides.
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Figure 3.2 Schematic of the Fmoc/tBu peptide synthesis.
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Figure 3.3 The typical spectrum of in an α-helix, β-sheet, and random coil
peptide

3.2 Materials
All peptide synthesis reagents including Fmoc-Wang resins, amino acids, N, N’Diisopropylcarbodiimide (DIC), N, N-Diisopropylethylamine (DIPEA),
triisopropylsilane (TIS), N-hydroxybenzotriazole (HOBT), 2-(1H-7-azabenzotriazol-1yl)-1,1,3,3 tetramethyluronium hexafluorophosphate (HATU), O-(Benzotriazol-1-yl)N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), piperidine, and 6aminohexanoic acid (Ahx) were purchased from Chem-Impex International Ltd (Wood
Dale, IL, USA). Solvents including dichloromethane (DCM), N, N’-dimethyl formamide
(DMF), and Acetonitrile (ACN) were of HPLC grade from Fisher Scientific (Pittsburgh,
PA, USA). Phenol, diethyl ether, and trifluoroacetic acid (TFA) were obtained from
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Acros organics (Pittsburgh, PA, USA). Acetic anhydride was obtained from
Mallinckrodt (St. Louis, MO, USA). Fluorescein isothiocyanate (FITC) was purchased
from Calbiochem (San Diego, CA, USA). All chemicals and solvents were used without
further purification.
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3.3 Methods
3.3.1 Synthesis of peptides. The peptides: PDL1-01-25MER, PDL1-06-13MER,
PDL1-P13-1, PDL1-P13-28, PDL1-P13-33, PDL1-P13-40, PDL1-P13-55, and PDL1P13-X were synthesized by the solid phase peptide synthesis method using standard
Fmoc chemistry (Table 3.1). First, the Wang resin (0.2 mmol scale) preloaded with the
C-terminal end amino acid of these different sequences was preswelled in DMF for 20
minutes, and the amino group of that amino acid was deprotected using 20% piperidine
in DMF for 30 minutes. After washing with both DMF and DCM three times, the Fmoc
protected amino acid was added with five equivalences of HBTU and HOBT and nine
equivalences of DIPEA for three hours. The Kaiser test was performed to estimate the
completeness of the coupling by observing the color of resin. The deprotection and
coupling procedures were repeated until the last amino acid at the end of N-terminal was
attached on to the resin. After every three coupling procedures, capping was performed
to block the intermediates that cannot be washed away by using acetic anhydride and
DIPEA in the DMF solution. At last, the cleavage of the peptide was conducted by
adding the cleavage cocktail of TFA, phenol, deionized water, and TIPS in the ratio
88:5:5:2 and reacting for three hrs. The TFA solution was added into ice-cold diethyl
ether to precipitate the peptides. The diethyl ether and peptide mixture were kept at 20˚C overnight to obtain the maximum amounts of products. Ice-cold diethyl ether was
used again to collect the precipitate by centrifuging and washing it three times. After
that, the peptides were all lyophilized and stored at -80˚C before further using.

69

3.3.2 Synthesis of FITC-peptide conjugations. In confocal microscopy studies,
FITC was commonly used to conjugate onto the N-terminus of the peptides as a
fluorescent probe. The Ahx (6-aminohexanoic acid), protected by Fmoc, was used as a
linker and was added to the N-terminus of the peptides using the same method as that of
amino acids. Three equivalents of FITC were dissolved in anhydrous DMF with 10
equivalents of DIPEA and agitated overnight in the dark. FITC-peptide conjugations
were then cleaved from the resin by using the cleavage cocktail containing TFA, phenol,
deionized water, and TIPS in the ratio 88:5:5:2 without the deprotection procedure.
After three hours of shaking, the mixture was added into ice-cold diethyl ether to form
precipitation. Ice-cold diethyl ether was used again to collect the precipitate by
centrifuging and washing it three times. After that, the FITC-peptide conjugations were
all lyophilized and stored at -80˚C before further using.
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3.3.3 Characterization of all peptides and FITC-peptide conjugations.
Peptides were characterized by MALDI-TOF (Shimadzu-Kratos PC Axima CFR V2.2.1)
using α-Cyano-4-hydroxycinnamic acid (CHCA) as a matrix or Electro-Spray Ionization
Mass Spectrometry (ESI-MS, Varian 320 ESI-triple-quadrupole mass spectrometer).
Samples were prepared in methanol and water in a 1:1 ratio. The purity of all
compounds was determined by high-performance liquid chromatography (HPLC),
Agilent 1100 Series, using Agilent Zorbax SB-C18, 3.5µm, 4.6 × 150 mm, column.
Water with 0.1% TFA (A) and acetonitrile with 0.1% TFA (B) were used as the mobile
phase. Both analyzation and purification were performed in the same HPLC column by
collecting the separated fractions, and then the peptides were lyophilized and stored at 80˚C before further analysis.
3.3.4 Characterization of secondary structure for peptides in alpha helix
design. The secondary structure for peptides in alpha helix design were characterized by
Spectra Manager Version 2 software in Jasco J-810 spectropolarimeter. Samples were
prepared in methanol and water in a 1:1 ratio.
3.4 Results and discussion
All peptides were successfully synthesized by the solid phase peptide synthesis
method. In the binding studies, these peptides without FITC will be tested with PD-L1
protein using the Surface Plasmon Resonance (SPR) technique. To build the peptide
chain, it is necessary to repeat deprotection and coupling protocols in the synthesis of
these peptides. Most of the amino acids were coupled using five folds excess in three
hours. However, a certain amino acid such as arginine took double couplings in two
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hours. HBTU, a stronger coupling agent with DIPEA, was performed to complete the
coupling procedure instead of DIC when the amino acid was not conjugated to the resin.
The presence of free primary amino groups was checked by the Kaiser test, which is a
useful way to determine the completeness of a coupling step. The peptides were
separated from the side products and other impurities by using HPLC with a
hydrophobic C18 column after the cleavage step. It was necessary to add 0.1% TFA into
the mobile phases since the behavior of some C18 columns greatly relied on strong ion
pairing agents that could enhance the shape and resolution of the peak. Additionally, it
was easy for TFA to volatilize and it had a low absorption within the detection
wavelengths. The desired peaks were finally separated and purified. The final purity of
the peptide is shown in Table 3.1 and HPLC peaks of all the peptides are shown from
Figures 3.15 to 3.20.
Different peaks were collected to identify and confirm by MS. All the peptides
with or without FITC were characterized by ESI MS. The MS results showed the desired
molecular weight of the peptides. The desired peptides with right molecular weight were
obtained from the analyses of the mass spectrum. The MS spectra are shown from
Figure 3.3 to 3.8.
FITC labeled peptides were synthesized as well for cellular uptake studies by
using the confocal microscopy technique. During cleavage, N-terminal FITC-labeled
peptides undergo a cyclization, resulting in the development of a fluorescein followed by
the removal of the last amino acid on the peptide. It is difficult to conjugate FITC onto
the N-terminus of the amino acid because of Edman degradation during the reaction
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which leads to an unexpected product. An alkyl spacer 6-aminohexanoic acid (Ahx) was
added at N-terminus of the peptide, and then the Ahx group provided FITC with space
which resulted in the acquiring of the desired product [112]. Additionally, the influence
of FITC to the binding/function of peptides can also be reduced by the attachment of the
Ahx group [113]. FITC labeled peptides were successfully synthesized based on the
analyses of the mass spectrum. The MS spectra of FITC labeled peptides are shown
from Figure 3.9 to 3.14. The MS results showed the desired molecular weight of the
peptide and were confirmed by the products with their m/z values detected in ESI-MS.
For all the FITC conjugated peptides, the final purity was checked by the HPLC analysis
using the same methods mentioned before. The final purity of the FITC labeled peptide
is shown in Table 3.1, and the HPLC peaks of all the FITC-peptides are shown from
Figures 3.21 to 3.26.
The secondary structure for peptides in alpha helix design was determined by
Circular Dichroism. The CD spectrum of PDL1-01-25MER is shown in Figure 3.27. The
results showed the desired figure but the low ratio of α-helical structure of peptide in
alpha helix design.
Peptides and FITC-peptides were successfully synthesized by using the solid
phase peptide synthesis and were characterized by MS and HPLC. FITC was
successfully conjugated to the N-terminus of the peptides. The binding specificity and
affinity towards PD-L1 will be discussed later.
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Table 3.1 Sequence of peptides for synthesis
Peptides
Primary structure

MW

HPLC Purity

[M+3H]3+

(%)

697.3

98

IAKARAQLEQFAS

478.4

94

PDL1-P13-01

RKIPLSIGQTHSE

550.2

99

PDL1-P13-28

RKFPLSKGQTHSE

505.8

99

PDL1-P13-33

RKFPSSFGQTHSE

503.4

95

PDL1-P13-40

RKIPHSKGQTHSE

502.4

95

FITC-PDL1-P13-01

FITC-RKIPLSIGQTHSE

717.7

93

FITC-PDL1-P13-28

FITC-RKFPLSKGQTHSE

673.4

95

FITC-PDL1-P13-33

FITC-RKFPSSFGQTHSE

670.9

94

FITC-PDL1-P13-40

FITC-RKIPHSKGQTHSE

669.9

94

FITC-PDL1-P13-55

FITC-RKVPHSIGQTHSE

660.3

96

FITC-PDL1-P13-X

FITC-RQSKLHPGSKTFE

673.4

93

PDL1-01-25MER

YGNLARKIAELEKLLAEAQQREALG

PDL1-06-13MER

(Control)
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Figure 3.4 ESI-MS spectrum of PDL1-01-25MER, MW: (M+3H)3+ 697.3
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Figure 3.5 ESI-MS spectrum of PDL1-06-13MER, MW: (M+3H)3+ 478.4
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Figure 3.6 ESI-MS spectrum of PDL1-P13-01, MW: (M+3H)3+ 550.2
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Figure 3.7 ESI-MS spectrum of PDL1-P13-28, MW: (M+3H)3+ 505.8

78

Figure 3.8 ESI-MS spectrum of PDL1-P13-33, MW: (M+3H)3+ 503.4

79

Figure 3.9 ESI-MS spectrum of PDL1-P13-40, MW: (M+3H)3+ 502.4
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Figure 3.10 ESI-MS spectrum of FITC-PDL1-P13-01, MW: (M+3H)3+ 717.7
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Figure 3.11 ESI-MS spectrum of FITC-PDL1-P13-28, MW: (M+3H)3+ 673.4
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Figure 3.12 ESI-MS spectrum of FITC-PDL1-P13-33, MW: (M+3H)3+ 670.9
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Figure 3.13 ESI-MS spectrum of FITC-PDL1-P13-40, MW: (M+3H)3+ 669.9
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Figure 3.14 ESI-MS spectrum of FITC-PDL1-P13-55, MW: (M+3H)3+ 660.3
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Figure 3.15 ESI-MS spectrum of FITC-PDL1-P13-X, MW: (M+3H)3+ 673.4
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Figure 3.16 HPLC chromatogram of PDL1-01-25MER
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Figure 3.17 HPLC chromatogram of PDL1-06-13MER
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Figure 3.18 HPLC chromatogram of PDL1-P13-01
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Figure 3.19 HPLC chromatogram of PDL1-P13-28
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Figure 3.20 HPLC chromatogram of PDL1-P13-33
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Figure 3.21 HPLC chromatogram of PDL1-P13-40
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Figure 3.22 HPLC chromatogram of FITC-PDL1-P13-01

20

25

min

93

15.756

DAD1 C, Sig=254,8 Ref=360,100 (XINGCHEN\042-0101.D)
mAU

80

60

24.676

40

1.887
2.033

20

0
0

5

10

15

Figure 3.23 HPLC chromatogram of FITC-PDL1-P13-28
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Figure 3.24 HPLC chromatogram of FITC-PDL1-P13-33
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Figure 3.25 HPLC chromatogram of FITC-PDL1-P13-40
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Figure 3.26 HPLC chromatogram of FITC-PDL1-P13-55
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Figure 3.27 HPLC chromatogram of FITC-PDL1-P13-X
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Figure 3.28 CD spectrum of PDL1-01-25MER peptide
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Chapter 4: In Vitro Binding Specificity, Affinity of Peptides to PDL1
4.1 Introduction
In the different areas of biomedicine, binding studies are significant and
meaningful for biomolecules. The increasing attention to the antibodies results in the
development of those binding methods. Specificity and affinity are the most important
properties in binding studies.
The binding specificity is one of the significant parameters of an antibody. For a
biomolecule, it is probable that there is not only one site to bind with, referred to as nonspecific binding, and is the reason why drugs have side effects. It is unacceptable if a
ligand doesn’t bind to its designated receptor. Therefore, it is necessary to focus on the
binding specificity studies.
Cell culture experiment is widely performed in binding specificity studies. The
expression for the interested protein on the cell is provided, and cancer cells are known
to overexpress certain receptors as compared to normal cells. Additionally, it is also
convenient to observe the biological activities with other molecules on the cells [114].
PD-L1 protein is found that overexpress on different cancer cells. In vitro,
cellular uptake studies with fluorophore associated imaging methods are widely used to
determine the binding specificity studies to PD-L1 in the lab. After incubating with cells,
the FITC labeled peptides can be detected and analyzed based on their localization and
visualization by using confocal laser scanning microscopy. Confocal microscopy is
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known to provide images with a better resolution and reduced background signal [115].
FITC conjugated peptides are used to check the binding specificity in confocal
microscopy experiments.
Different from cell binding studies, determination of the binding affinity is
important as well. The binding affinity between a ligand and a receptor is widely
determined by the equilibrium dissociation constant (KD). A high affinity means a strong
binding which comes with a small KD. There are many solutions such as cell-based
binding assays with FITC labeled peptides to find KD values in the receptor-ligand
system. Additionally, competition assays with unlabeled and labeled peptides can be
employed to obtain the binding constant. However, it is difficult to find the accurate
mount of proteins on the cells performed in the experiments and this leads to inaccurate
results of binding affinity. What’s more, some properties of the peptides can be changed
when peptides are labeled with different agents, which means the function of these
labeled agents is also unpredictable.
There are many immunoassays such as Surface Plasmon Resonance (SPR),
enzyme-linked immunosorbent assays (ELISA), and radioimmunoassay (RIA) for
binding affinity studies. Surface Plasmon Resonance (SPR) is one of the quantitative
approaches to observe real-time binding activity. SPR is an efficient label-free method
that can be performed to calculate the equilibrium dissociation constant between two
biomolecules in real time [116,117]. When an analyte binds to the target protein, there
will be a change in the refractive index, resulting in the alteration in the resonance angle
in SPR. The molecule that is flown over and that binds to the immobilized target on a
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gold sensor chip is referred to as an analyte [118,119]. The real-time binding
information can be obtained in SPR when it compares with fluorescent polarization
study that is performed with the fluorescent probe for a relative binding constant.
The binding specificity studies were performed by cellular uptake studies using
two different cell lines including PD-L1 positive cell line, MDA-MB-231, and control
cell lines, MCF-7. MDA-MB-231 is a breast cancer cell line known to express PD-L1 at
a high level, and MCF-7 is also a breast cancer line used as a control for binding
specificity studies [120]. After labeling with FITC, it is easy to determine whether they
can bind specifically to PD-L1 positive cells and observe the visualization and location
of the peptides by using confocal microscopy. Binding affinity can be determined by the
affinity constant and response sensorgram using SPR in a real-time approach.
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Figure 4.1 A typical SPR set up.

A typical SPR set up is shown here in Figure 4.1. It has a light source, a prism, a
golden chip, a flow channel, and a detector. The light source provides polarized light for
the system. The prism can reflect the polarized light to different angles based on the
binding conditions between the analytes and protein. The molecules immobilized in the
golden chip and solution of analytes are injected in the flow channel. All the polarized
light comes to the detector and becomes an SPR sensorgram.
The light generated by the light source can hit the top of the sensor golden chip
and prism. When analytes flow through the flow channel and bind to the target protein,
there will be a shift in the refractive index of the sensor chip. The detector can collect
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the reflected light with the different angles caused by these changes in real time and the
data can be shown in a sensorgram.

Figure 4.2 A typical sensorgram from SPR.

A typical sensorgram is shown here in Figure 4.2. It has three main phases, the
association phase, the equilibrium phase, and the dissociation phase. In the association
phase, an increase in the SPR response signal is detected when the analyte starts to bind
the immobilized protein. In the steady state, the binding sites become saturated and the
response is unchanged for several seconds. This phase is called the equilibrium phase.
After the equilibrium phase, a decrease in SPR response is observed which means the
analyte starts dissociating. This final phase is termed as the dissociation phase.
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4.2 Materials
PD-L1 positive cells MDA-MB-231 and the control cell MCF-7 were purchased
from ATCC (Manassas, VA, USA). The cells were cultured in Dulbecco’s modified
eagle’s medium (DMEM) with 4.5g/L glucose, L-glutamine, and sodium pyruvate from
Cellgro, Mediatech Inc (Manassas, VA, USA). Penicillin-Streptomycin was also
obtained from Cellgro, Mediatech Inc. (Manassas, VA, USA). Trypsin: EDTA was
bought from GEMINI (West Sacramento, CA, USA). Phosphate Buffered Saline (PBS)
pH 7.2, hyclone Fetal Bovine Serum (FBS) was purchased from Thermo Scientific
(Logan, UT, USA). Human PDL-1 Protein was purchased from Sino Biological Inc.
(Beijing, China). All microscopy supplies were purchased from VWR (USA). Cell
culture supplies were purchased from Santa Cruz Biotechnology Inc. (TX, USA) and
Cellgro, Mediatech Inc. (Manassas, VA, USA).
Alexa fluor 594 wheat germ agglutinin and Slow fade gold mounting medium
were purchased from Invitrogen (Carlsbad, CA, USA). Phosphate buffered saline, pH
7.4, contains TWEEN® 20, dry powder, N-ethyl-N’-(3-dimethylaminopropyl)
carbodiimide (EDC), N-hydroxysuccinimide (NHS), Ethanolamine (EA), Glycine, and
Bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). All chemicals and solvents were used without further purification.
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4.3 Methods
4.3.1 Cell culture. DMEM was used as the cell culture media to which 10% FBS
and 1% penicillin-streptomycin (5000 I.U./mL) were added and then refrigerated. MDAMB-231 and MCF-7 cells were incubated in a T75 flask in the prepared cell culture
media at 37˚C and 5% CO2 and were subcultured when the cells reach 80% confluency.
Additionally, cells were frozen in the recovery freezing media (DMEM with 5% DMSO)
and stored in a nitrogen tank for future experiments.
4.3.2 Confocal microscopy studies. MDA-MB-231 and MCF-7 cells were
grown in T75 flasks at 37˚C and 5% CO2. 2× 105 cells were seeded on coverslips placed
inside six well-cultured plates when the confluency reached about 80%. The experiment
was carried out after 24 hours of attachment. After the medium was removed, the cells
were washed twice with PBS and serum-free media.
FITC labeled peptides and control peptide were dissolved and diluted in serumfree DMEM with 1% dimethyl sulfoxide (DMSO). The final solutions of all peptides at
the concentration of 20μM were added to the six well-cultured plates.
After incubating for 25 minutes at 37˚C, the cells were washed twice with PBS
and then treated with a solution of Alexa Fluor 594 wheat germ agglutinin in PBS at 2.5
µg/mL for 10 minutes to stain the cell plasma membrane. After that, cells were washed
twice with PBS and then fixed by 4% paraformaldehyde solution prepared in PBS for 15
minutes. Then, a final wash of distilled water was performed after washing PBS twice.
The coverslips with the fixed cells were covered on the microscopic slides with a drop of
the mounting medium (slow fade gold). The cells were imaged on an inverted Leica
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DMIRE2 confocal laser scanning microscope (Leica Biosystems Richmond Inc,
Richmond, USA) with Yokogawa CSU-X1 confocal scanner unit at 64x magnification
and oil immersion (Yokogawa Electric Corporation, Japan). The FITC labeled peptides
were observed under the 491 nm channel, and the cell plasma membrane stained by
Alexa Fluor 594 fluorescence was visualized under the 561 nm channel.
A semiquantitative method of fluorescence intensity for peptides with salt bridge
function was performed based on the cell images from confocal microscopy studies. The
mean fluorescence intensity of ten cells in different cell images was determined and
calculated from ImageJ.
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4.3.3 Binding affinity studies using SPR. The binding affinity of peptides was
calculated by the Dual Channel SPR Spectrometer SPR7000DC (Reichert Technologies,
New York, USA) in SPR studies. N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were employed to activate the
Carboxymethyl Dextran Hydrogel Surface Sensor Chip (Reichert Technologies, New
York, USA) under the running buffer of phosphate buffered saline with 0.05% Tween 20
(pH7.4) that was degassed before using at room temperature. Then, ethanolamine (EA)
pH 8.5 was injected to block unreactive sites for eight minutes at a rate of 10µL/min.
Human PD-L1 protein (25µg/ml) and bovine serum albumin (BSA, 20µg/ml) were used
as the control and were diluted and immobilized by flowing them over the left channel
of the activated chip in 10 mM sodium acetate buffer pH 4.5. The real-time binding
response for peptides (PDL1-01-25MER, PDL1-06-13MER, PDL1-P13-1, PDL1-P1328, PDL1-P13-33, PDL1-P13-40) over PD-L1 were observed at an injection speed of
25µL/min in the SPR software. PDL1-P13-28 was also injected with BSA protein.
Additionally, 10 mM glycine (pH 2.5) in PBST can be performed to regenerate the
bound surface of the activated chips[193]. The sensorgrams from SPR were all analyzed
using the Scrubber 2® software (BioLogic Software Pty Ltd, Australia) in the terms of
zeroed, aligned, referenced, and blanked. The association rate (ka), dissociation rate
(kd), and dissociation constant (KD) were also determined by using the Scrubber 2®
software global in a 1:1 Lagmurian interaction model.
4.4 Results and discussion
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Three generations of peptides against PD-L1 protein were designed based on the
Knob-Socket model. After screening in MOE and the AutoDock Vina software, top
peptides with lower energy were selected based on the docking results. Lower binding
energy and more interaction sites with PD-L1 were also observed in the peptides
designed in salt bridge function from MOE and the AutoDock Vina docking results.
Experiments were performed to validate the docking results from the computational
modeling method and test the binding specificity and affinity of the designed peptides.
The affinity of the designed peptides to PD-L1 protein was determined in SPR
studies. Response sensorgrams of three generations of peptides with PD-L1 collected
from SPR studies are shown in Figure 4.3-4.9. All response sensorgrams were obtained
from the Scrubber software.
No binding responses for α-helix and over-packed peptides were observed in
SPR sensorgram which suggested peptides designed in α-helix and over-packed method
were not feasible. A reasonable explanation is the original α-helix design may have
broken due to the improper position of knobs in the PD-L1 Knob-Socket receptor frame
pattern and the low ratio of alpha-helical structure, resulting in the loss of knobs fit into
their sockets for α-helix peptides. Additionally, due to the limited space, it is too
congested for over-packed peptides to bind to the PD-L1 protein.
When compared with the first and second generations of peptides which
designed in α-helix and over-packed method, the third generation of peptides designed
with the new binding information, salt bridge, had a much higher binding response. For
PDL1-04-25MER and PDL1-06-13MER, they have no response based on the
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sensorgram, while PDL1-P13-1, PDL1-P13-28, PDL1-P13-33, and PDL1-P13-40 had a
response unit around 15. The SPR results of the response for third generation peptides
toward the BSA protein is shown in Figure 4.9. From the results, we can find that
peptides showed no binding to BSA protein, which means those designed peptides have
a binding specificity. These data are a clear evidence that the third generations of
peptides with salt bridge function can bind to the PD-L1 protein. However, KD values
can’t be obtained since there was only a slight change when the concentrations of
peptides increased. Though affinity of peptides against PD-L1 can’t be calculated, the
binding between peptides and PD-L1 was further verified using the cell uptake
experiments.
The in vitro binding specificity of peptides to the PD-L1 positive cancer cells
was determined in confocal microscopy studies. In confocal microscopy studies,
significant fluorescence was detected on the cellular surfaces of MDA-MB-231, while
no fluorescence was detected on MCF-7 cells from cell images (Figures 4.11-4.16) after
incubation with 20 µM of FITC labeled peptides solution, which indicates that FITC
conjugated peptides can bind to MDA-MB-231 but not to MCF-7 cells. On the contrary,
no significant fluorescence was observed from both the two cell lines after incubation
with FITC labeled control peptide with a scrambled sequence PDL1-P13-X solution. A
plausible explanation is the knob and socket pairs may have broken, resulting in the loss
of knobs fit into their sockets. To preserve the binding specificity, the peptide with
different amino acids as knobs on the sequence should fit the right sockets on the PD-L1
protein.
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The result of the significant fluorescence of MDA-MB-231 can be explained by
the specific interaction between PD-L1 and designed peptides, which was consistent
with the SPR results shown above.
To determine the visualization and localization of the cell, the cell plasma
membrane was marked by the Alexa Flour 594 dye in the confocal microscopy studies.
First, free FITC was used to see whether it can go inside the cell lines, and in Figure
4.10 results showed that free FITC can go inside both the two cell lines as a small
molecule. In Figures 4.11-4.16, peptides showed internalization by cells instead of
binding on the cell surface. The internalization of peptides can be attributed to receptormediated endocytosis upon binding onto the PD-L1 protein. Additionally, peptides are
much smaller when compared with antibodies, and as a result, it is much easier for
peptides to internalize into cells. Results from the confocal microscopy studies
suggested that the peptides with salt bridge function can bind to the PD-L1 positive cell
lines but not to the control cell lines.
A semiquantitative method of fluorescence intensity for peptides with salt bridge
function was performed based on the cell images from confocal microscopy studies. The
mean fluorescence intensity of ten cells in cell images for different peptides designed in
salt bridge function was shown in Figure 4.17. There is a significant difference in
fluorescence intensity between PD-L1 positive cell line and control cell line for peptides
designed in salt bridge function, while a tiny difference for the FITC labeled control
peptide with a scrambled sequence PDL1-P13-X. AutoDock Vina was used to perform a
second screening for the selected peptides from the MOE software. From the Figure 2.9,

111

we can determine that only PDL1-P13-55 can bind to the designed part of the target
protein. The PDL1-P13-55 with the lowest binding energy, which can bind to the
designed part of the target protein based on the docking results from Vina, had a higher
fluorescence intensity, when compared with the other five peptides in the figure, which
indicates the potential of binding ability against PD-L1 Protein.
The in vitro binding specificity of peptides towards PD-L1 was determined in the
confocal microscopy and SPR studies. Results showed that the peptides with salt bridge
function based on the Knob-Socket model and molecular interaction can bind to PD-L1
protein while α-helix and over-packed peptides can’t bind to the PD-L1 protein.
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Figure 4.3 SPR response of PDL1-01-25MER
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Figure 4.4 SPR response of PDL1-06-13MER
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Figure 4.5 SPR response of PDL1-P13-40
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Figure 4.6 SPR response of PDL1-P13-01
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Figure 4.7 SPR response of PDL1-P13-28
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Figure 4.8 SPR response of PDL1-P13-33
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Figure 4.9 SPR response of PDL1-P13-40 against BSA
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Figure 4.10 Evaluation of binding specificity of Free FITC to MDA-MB-231 and MCF-7 cells as
conformed by confocal microscopy.
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Figure 4.11 Evaluation of binding specificity of FITC-PDL1-P13-01 to MDA-MB-231 and MCF-7 cells
as conformed by confocal microscopy.
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Figure 4.12 Evaluation of binding specificity of FITC-PDL1-P13-28 to MDA-MB-231 and MCF-7 cells
as conformed by confocal microscopy.
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Figure 4.13 Evaluation of binding specificity of FITC-PDL1-P13-33 to MDA-MB-231 and MCF-7 cells
as conformed by confocal microscopy.

123

Alexa Fluor 594

Overlap

MCF-7 (control)

MDA-MB-231

FITC-PDL1-P13-40

Figure 4.14 Evaluation of binding specificity of FITC-PDL1-P13-40 to MDA-MB-231 and MCF-7 cells
as conformed by confocal microscopy.
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Figure 4.15 Evaluation of binding specificity of FITC-PDL1-P13-55 to MDA-MB-231 and MCF-7 cells
as conformed by confocal microscopy.
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Figure 4.16 Evaluation of binding specificity of FITC-PDL1-P13-X (control) to MDA-MB-231 and MCF-7
cells as conformed by confocal microscopy.
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Figure 4.17 Fluorescence intensity for different peptides designed in salt bridge function
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Chapter 5: Summary and Conclusions

Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein that has
been reported to play a vital role in mediating suppressed immunity. The interaction
between PD-L1 and PD-1 delivers a negative signal that reduces the proliferation of
these T cells. Specific antibodies, peptides, and small molecules are developed by
scientists to bind with PD-L1. Antibodies that can block the Programmed death-ligand 1
(PD-L1) on tumor cells have shown to alleviate cancer-induced immunosuppression.
While antibodies have a great potential in various therapeutic uses, many drawbacks
such as high cost of production, huge molecular size, and poor permeability impose
restrictions on the extensive use of full-length antibodies. Compared to antibodies,
peptides that selectively bind to PD-L1 have advantages in solubility, permeability, and
immunogenicity. The phage display technique or the computational screen of a large
library of thousands of candidates are used to develop antibody alternatives. However,
all these approaches are tedious, labor-intensive, and time-consuming due to their trialand-error nature.
In this study, it is hypothesized that rationally designed peptides based on PDL1-PD1 molecular interactions and the Knob-Socket computational model can bind to
PD-L1. Peptides against PD-L1 were designed based on the interaction between PD-L1
and PD-1 without involving massive experimental screening trials. Sequences of these
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peptides were obtained from the core amino acids in the binding surface between the
PD-L1-PD1 complex by using the Knob-Socket model and further docked in MOE and
Vina. The 2D map of peptides against PD-L1 with binding sites was obtained based on
the Knob-Socket model. Three generations of peptides, α-helix, over-packed, and new
peptides with the salt bridge function were designed and synthesized by using the Solid
Phase Synthesis method (SPPS). The top 20% peptides were selected based on the
binding energy simulated by MOE and AutoDock Vina before the binding affinity and
specificity experiment. Peptide PDL1-P13-55 can bind to the right position which is
designed to be bound based on the docking studies. The salt bridge function peptides
with a lower binding energy and with a more number of interactions showed the binding
preference against the PD-L1 protein, based on the docking results from MOE and
AutoDock Vina. The binding between the designed peptides and PD-L1 was verified in
vitro binding affinity and specificity experiments. The Surface Plasmon Resonance
(SPR) technique was performed to determine the binding affinity of all the designed
peptides. Only peptides with the salt bridge function have a high response while the αhelix and over-packed peptides have no response on SPR sensorgrams. The confocal
microscopic studies using different cell lines showed that third generations of peptides
with salt bridge function bind specifically to PD-L1 positive cell line, MDA-MB-231,
but not to PD-L1 control cell line, MCF-7. The salt bridge function peptides with a
lower binding energy and with a more number of interactions selected based on the
docking results from MOE and AutoDock Vina showed good binding specificity
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towards PD-L1, which was confirmed based on the binding responses from SPR and the
fluorescence intensity from confocal microscopic studies.
In conclusion, peptides against PD-L1 designed rationally by the Knob-Socket
model and the molecular interaction between the PD-L1-PD1 complex showed good
binding specificity towards PD-L1, demonstrating the feasibility of this model in the
design of binding ligands for targeting delivery.
In the future, novel peptides can be used as a biomarker for the detection of PDL1 in various studies. The novel peptides can also be conducted as a targeting moiety of
a peptide drug conjugate in PD-L1 positive cancers therapy. Cellular cytotoxicity studies
can be performed to evaluate the potential of novel peptides to be used as targeting
moiety of anticancer drugs.
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